-
What Fovista's Fail Means For OHR Pharma
Tuesday, December 13, 2016 - 9:22am | 324Read More...On September 30, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced Phase 2 results for rinucumab, with the drug not meeting the primary endpoint of the study. On December 12, Ophthotech Corp (NASDAQ: OPHT) announced Phase 3 results for Fovista, which also did not achieve the primary...
-
OHR Pharmaceutical Gains 7% Following Agreement With FDA
Tuesday, March 29, 2016 - 9:05am | 190Read More...Shares of OHR Pharmaceutical Inc (NASDAQ: OHRP), a nano-cap pharmaceutical company that focuses on the treatment of ocular diseases, spiked higher by more than 7 percent early Tuesday morning. OHR Pharmaceutical announced it has reached an agreement on the Special Protocol Assessment (SPA) with the...
